Drug intelligence / Profile preview

donepezil + galantamine + rivastigmine

Development stage: Unknown
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral, Transdermal

Overview

This represents a combination of three separate acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) that are used in the treatment of Alzheimer's disease. Each drug works by inhibiting acetylcholinesterase to increase acetylcholine levels in the brain, which may improve cognitive function in patients with dementia. These medications are typically prescribed individually rather than as a fixed-dose combination.

Brand names: AriceptExelonRazadyneReminyl
Other names: Cholinesterase InhibitorsAChEIsAcetylcholinesterase inhibitors

Targets

ButyrylcholinesteraseAcetylcholinesteraseNicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on donepezil + galantamine + rivastigmine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + galantamine + rivastigmine.

Explore the full profile